ReviewCancers2023
Tumor Organoid and Spheroid Models for Cervical Cancer.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 20 citations in OpenAlex.
- Cellular plasticity and heterogeneity underlying therapy resistance in 3D cervical cancer models.Hereditas · 2026Review
- The Chick Embryo Chorioallantoic Membrane Assay as a Short-Term Exploratory Model for Cervical Cancer Research.Life (Basel, Switzerland) · 2026Article
- Inflammasomes meet organoids and artificial intelligence: unraveling the complexity of gynecological inflammation.Frontiers in immunology · 2026Review
- Discovery of inhibitors of the cancer-promoting phosphatase PRL-3 and their evaluation in intestinal organoids.Bioorganic & medicinal chemistry · 2025Article
- Erucic Acid, Derived by Lactobacillus Crispatus, Induces Ferroptosis in Cervical Cancer Organoids Through the PPAR-δ Signaling Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A Robust Marine Collagen Peptide-Agarose 3D Culture System for In Vitro Modeling of Hepatocellular Carcinoma and Anti-Cancer Therapeutic Development.Marine drugs · 2025Article
- Advanced Three-Dimensional Cell Culture Models for Investigating EnterohaemorrhagicJournal of microbiology and biotechnology · 2025Review
- Targeting Metastasis: Exploring the Impact of Microbial Infections on Cancer Progression Through Innovative Biological Models.Current microbiology · 2025Review
- Review
- Dual Topoisomerase Inhibitor Is Highly Potent and Improves Antitumor Response to Radiotherapy in Cervical Carcinoma.International journal of molecular sciences · 2025Article
- Frontier progress and translational challenges of pluripotent differentiation of stem cells.Frontiers in genetics · 2025Review
- Organoid technology in cervical cancer research.American journal of cancer research · 2025Review
- Article
- TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges.Journal of translational medicine · 2024Review
- Review
- Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-oncology Research.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- A Marine Collagen-Based 3D Scaffold for In Vitro Modeling of Human Prostate Cancer Niche and Anti-Cancer Therapeutic Discovery.Marine drugs · 2024Article
- Differentiation States of Phenotypic Transition of Melanoma Cells Are Revealed by 3D Cell Cultures.Cells · 2024Article
- Three-DimensionalInternational journal of biological sciences · 2024Review
- A Comprehensive Review of Genistein's Effects in Preclinical Models of Cervical Cancer.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Cervical cancer is one of the most common malignant diseases in women worldwide. Despite the global introduction of a preventive vaccine against the leading cause of cervical cancer, human papillomavirus (HPV) infection, the incidence of this malignant disease is still very high, especially in economically challenged areas. New advances in cancer therapy, especially the rapid development and application of different immunotherapy strategies, have shown promising pre-clinical and clinical results. However, mortality from advanced stages of cervical cancer remains a significant concern. Precise and thorough evaluation of potential novel anti-cancer therapies in pre-clinical phases is indispensable for efficient development of new, more successful treatment options for cancer patients. Recently, 3D tumor models have become the gold standard in pre-clinical cancer research due to their capacity to better mimic the architecture and microenvironment of tumor tissue as compared to standard two-dimensional (2D) cell cultures. This review will focus on the application of spheroids and patient-derived organoids (PDOs) as tumor models to develop novel therapies against cervical cancer, with an emphasis on the immunotherapies that specifically target cancer cells and modulate the tumor microenvironment (TME).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.